Safe drug use in long QT syndrome and Brugada syndrom

Europace

Volumn 15, Issue 7, 2013, Pages 1042-1049

  Postema, Pieter G ^a,b   Neville, Jon ^b   De Jong, Jonas S S G ^a,b   Romero, Klaus ^c,d   Wilde, Arthur A M ^a,b   Woosley, Raymond L ^d  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b Cardionetworks Foundation   (Netherlands)

^c CRITICAL PATH INSTITUTE   (United States)

^d AZCERT Inc and NDA Partners LLC   (United States)

Author keywords

Brugada syndrome; Cardiac arrest; Drugs; Long QT syndrome; Side effects; website statistics; website use

Indexed keywords

ADULT; AFRICA; ARTICLE; ASIA; BRUGADA SYNDROME; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG SAFETY; DRUG USE; EUROPE; FEMALE; HEALTH CARE SURVEY; HUMAN; LONG QT SYNDROME; MAJOR CLINICAL STUDY; MALE; ONLINE ANALYSIS; OUTCOME ASSESSMENT; PACIFIC ISLANDS; PRIORITY JOURNAL; STATISTICAL ANALYSIS; WESTERN HEMISPHERE;

BRUGADA SYNDROME; CARDIAC ARREST; DRUGS; LONG QT SYNDROME; SIDE EFFECTS; WEBSITE STATISTICS; WEBSITE USE;

ADULT; BRUGADA SYNDROME; DEATH, SUDDEN, CARDIAC; DRUG INFORMATION SERVICES; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; INTERNET; LONG QT SYNDROME; MALE; MIDDLE AGED; PATIENT EDUCATION AS TOPIC; PROSPECTIVE STUDIES; QUESTIONNAIRES; RISK FACTORS; TREATMENT OUTCOME;

EID: 84879587672     PISSN: 10995129     EISSN: 15322092     Source Type: Journal    
DOI: 10.1093/europace/eut018     Document Type: Article

References (28)

1. Ackerman MJ, Priori SG, Willems S, Berul C, Brugada R, Calkins H et al. HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies: this document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA). Europace 2011;13:1077-109.
2. Ackerman MJ, Priori SG, Willems S, Berul C, Brugada R, Calkins H et al. HRS/EHRA Expert consensus statement on the state of genetic testing for the channe-lopathies and cardiomyopathies. Heart Rhythm 2011;8:1308-39.
3. De Bruin ML, Langendijk PN, Koopmans RP, Wilde AA, Leufkens HG, Hoes AW. In-hospital cardiac arrest is associated with use of non-antiarrhythmic QTc-prolonging drugs. Br J Clin Pharmacol 2007;63:216-23.
4. Sicouri S, Antzelevitch C. Sudden cardiac death secondary to antidepressant and antipsychotic drugs. Expert Opin Drug Saf 2008;7:181-94.
5. Straus SM, Sturkenboom MC, Bleumink GS, Dieleman JP, Van der LJ, De Graeff PA et al. Non-cardiac QTc-prolonging drugs and the risk of sudden cardiac death. Eur Heart J 2005;26:2007-12.
6. Postema PG, Wolpert C, Amin AS, Probst V, Borggrefe M, Roden DM et al. Drugs and Brugada syndrome patients: review of the literature, recommendations, and an up-to-date website (www.brugadadrugs.org). Heart Rhythm 2009;6:1335-41.
7. Sze E, Moss AJ, Goldenberg I, McNitt S, Jons C, Zareba W et al. Long QT syndrome in patients over 40 years of age: increased risk for LQTS-related cardiac events in patients with coronary disease. Ann Noninvasive Electrocardiol 2008;13: 327-31.
8. Viskin S, Rosso R, Marquez MF, Antzelevitch C. The acquired Brugada syndrome and the paradox of choice. Heart Rhythm 2009;6:1342-4.
9. Kolder ICRM, Tanck MWT, Bezzina CR. Common genetic variation modulating cardiac ECG parameters and susceptibility to sudden cardiac death. J Mol Cell Cardiol 2012;52:620-9.
10. Vincent GM, Schwartz PJ, Denjoy I, Swan H, Bithell C, Spazzolini C et al. High efficacy of beta-blockers in Long-QT syndrome type 1. Contribution of noncompli-ance and QT-prolonging drugs to the occurrence of beta-blocker treatment 'failures'. Circulation 2008;119:215-21.
11. Schwartz PJ, Stramba-Badiale M, Crotti L, Pedrazzini M, Besana A, Bosi G et al. Prevalence of the congenital long-QT syndrome. Circulation 2009;120:1761-7.
12. Postema PG. About Brugada syndrome and its prevalence. Europace 2012;14: 925-8.
13. ′ untranslated region of the KCNQ1-encoded Kv7.1 potassium channel modify disease severity in patients with type 1 long QT syndrome in an allele-specific manner. Eur Heart J 2012;33:714-23.
14. Barsheshet A, Goldenberg I, O-Uchi J, Moss AJ, Jons C, Shimizu W et al. Mutations in cytoplasmic loops of the KCNQ1 channel and the risk of life-threatening events: implications for mutation-specific response to b-blocker therapy in type 1 Long-QT syndrome. Circulation 2012;125:1988-96.
15. Wilde AA, Viskin S. EP testing does not predict cardiac events in Brugada syndrome. Heart Rhythm 2011;8:1598-600.
16. Brugada J, Brugada R, Brugada P. Electrophysiologic testing predicts events in Brugada syndrome patients. Heart Rhythm 2011;8:1595-7.
17. Makita N, Behr E, Shimizu W, Horie M, Sunami A, Crotti L et al. The E1784K mutation in SCN5A is associated with mixed clinical phenotype of type 3 long QT syndrome. J Clin Invest 2008;118:2219-29.
18. Postema PG, Van den Berg MP, Van Tintelen JP, Van den Heuvel F, Grundeken M, Hofman N et al. Founder mutations in the Netherlands. SCN5a 1795insD, the first described arrhythmia overlap syndrome and one of the largest and best described characterised families worldwide. Neth Heart J 2009;17:422-8.
19. Van Gorp V, Danschutter D, Huyghens L, Hachimi-Idrissi S, Sarkozy A, Chierchia GB et al. Monitoring the safety of antiepileptic medication in a child with Brugada syndrome. Int J Cardiol 2010;145:e64-7.
20. Zipes DP, Camm AJ, Borggrefe M, Buxton AE, Chaitman B, Fromer M et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death) developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Europace 2006;8:746-837.
21. Goldenberg I, Bradley J, Moss A, McNitt S, Polonsky S, Robinson JL et al. Beta-blocker efficacy in high-risk patients with the congenital Long-QT syndrome types 1 and 2: implications for patient management. J Cardiovasc Electrophysiol 2010;21:893-901.
22. Wilde AA, Kaufman ES, Shimizu W, Moss AJ, Benhorin J, Lopes CM et al. Sodium channel mutations, risk of cardiac events, and efficacy of beta-blocker therapy in type 3 Long QT syndrome (abstract). Heart Rhythm 2012;9:S321.
23. Valdivia CR, Ackerman MJ, Tester DJ, Wada T, McCormack J, Ye B et al. A novel SCN5A arrhythmia mutation, M1766L, with expression defect rescued by mexi-letine. Cardiovasc Res 2002;55:279-89.
24. Moss AJ, Zareba W, Schwarz KQ, Rosero S, McNitt S, Robinson JL. Ranolazine shortens repolarization in patients with sustained inward sodium current due to type-3 Long-QT syndrome. J Cardiovasc Electrophysiol 2008;19:1289-93.
25. Viskin S, Wilde AA, Tan HL, Antzelevitch C, Shimizu W, Belhassen B. Empiric quinidine therapy for asymptomatic Brugada syndrome: time for a prospective registry. Heart Rhythm 2009;6:401-4.
26. Belhassen B, Glick A, Viskin S. Excellent long-term reproducibility of the electro-physiologic efficacy of quinidine in patients with idiopathic ventricular fibrillation and Brugada syndrome. Pacing Clin Electrophysiol 2009;32:294-301.
27. Mizusawa Y, Sakurada H, Nishizaki M, Hiraoka M. Effects of low-dose quinidine on ventricular tachyarrhythmias in patients with Brugada syndrome: low-dose quini-dine therapy as an adjunctive treatment. J Cardiovasc Pharmacol 2006;47:359-64.
28. Eysenbach G. Improving the quality of Web surveys: the Checklist for Reporting Results of Internet E-Surveys (CHERRIES). J Med Internet Res 2004;6:e34.